Do analysts recommend CELU or FBLG?

FibroBiologics has a consensus price target of $73.00, indicating a potential upside of 4,546.72%. Given FibroBiologics' stronger consensus rating and higher possible upside, analysts clearly believe FibroBiologics is more favorable than Celularity. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celularity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 FibroBiologics 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80

Is FBLG or MGX more profitable?

FibroBiologics has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -63.65% beat FibroBiologics' return on equity. Company Net Margins Return on Equity Return on Assets FibroBiologics N/A -536.78% -225.12% Metagenomi -384.61% -63.65% -44.52%

Does the media refer more to FBLG or MGX?

In the previous week, FibroBiologics had 2 more articles in the media than Metagenomi. MarketBeat recorded 5 mentions for FibroBiologics and 3 mentions for Metagenomi. Metagenomi's average media sentiment score of 1.60 beat FibroBiologics' score of 0.37 indicating that Metagenomi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment FibroBiologics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Metagenomi 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts prefer IZTC or FBLG?

FibroBiologics has a consensus target price of $73.00, indicating a potential upside of 4,546.72%. Given FibroBiologics' stronger consensus rating and higher possible upside, analysts plainly believe FibroBiologics is more favorable than Invizyne Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 FibroBiologics 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80

Which has better valuation & earnings, IZTC or FBLG?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Invizyne Technologies N/A N/A N/A N/A N/A FibroBiologics N/A N/A -$18.65M -$5.19 N/A

Is IZTC or FBLG more profitable?

Invizyne Technologies' return on equity of 0.00% beat FibroBiologics' return on equity. Company Net Margins Return on Equity Return on Assets Invizyne Technologies N/A N/A N/A FibroBiologics N/A -536.78% -225.12%

Does the media favor IZTC or FBLG?

In the previous week, FibroBiologics had 4 more articles in the media than Invizyne Technologies. MarketBeat recorded 5 mentions for FibroBiologics and 1 mentions for Invizyne Technologies. FibroBiologics' average media sentiment score of 0.37 beat Invizyne Technologies' score of 0.00 indicating that FibroBiologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Invizyne Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral FibroBiologics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to GOSS or FBLG?

In the previous week, Gossamer Bio had 3 more articles in the media than FibroBiologics. MarketBeat recorded 8 mentions for Gossamer Bio and 5 mentions for FibroBiologics. FibroBiologics' average media sentiment score of 0.37 beat Gossamer Bio's score of -0.13 indicating that FibroBiologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gossamer Bio 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral FibroBiologics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is MREO or FBLG more profitable?

Mereo BioPharma Group's return on equity of -74.82% beat FibroBiologics' return on equity. Company Net Margins Return on Equity Return on Assets Mereo BioPharma Group N/A -74.82% -64.28% FibroBiologics N/A -536.78% -225.12%

FibroBiologics (FBLG) Competitors

$1.56 -0.05 (-2.98%)

As of 11:46 AM Eastern

Compare

FBLG vs. CELU, MGX, IZTC, GOSS, and MREO

Should you buy FibroBiologics stock or one of its competitors? FibroBiologics's main competitors and comparable companies include Celularity (CELU), Metagenomi (MGX), Invizyne Technologies (IZTC), Gossamer Bio (GOSS), and Mereo BioPharma Group (MREO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does FibroBiologics compare to Celularity?

Celularity (NASDAQ:CELU) and FibroBiologics (NASDAQ:FBLG) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

In the previous week, FibroBiologics had 3 more articles in the media than Celularity. MarketBeat recorded 5 mentions for FibroBiologics and 2 mentions for Celularity. Celularity's average media sentiment score of 0.44 beat FibroBiologics' score of 0.37 indicating that Celularity is being referred to more favorably in the media.

Company	Overall Sentiment
Celularity	Neutral
FibroBiologics	Neutral

FibroBiologics has lower revenue, but higher earnings than Celularity. Celularity is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55M	1.46	-$91.72M	-$3.33	N/A
FibroBiologics	N/A	N/A	-$18.65M	-$5.19	N/A

19.0% of Celularity shares are owned by institutional investors. 17.3% of Celularity shares are owned by insiders. Comparatively, 7.3% of FibroBiologics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Celularity has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market. Comparatively, FibroBiologics has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market.

FibroBiologics has a consensus price target of $73.00, indicating a potential upside of 4,546.72%. Given FibroBiologics' stronger consensus rating and higher possible upside, analysts clearly believe FibroBiologics is more favorable than Celularity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
FibroBiologics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

FibroBiologics has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celularity	-345.45%	N/A	-77.94%
FibroBiologics	N/A	-536.78%	-225.12%

Summary

FibroBiologics beats Celularity on 8 of the 15 factors compared between the two stocks.

How does FibroBiologics compare to Metagenomi?

FibroBiologics (NASDAQ:FBLG) and Metagenomi (NASDAQ:MGX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

FibroBiologics has higher earnings, but lower revenue than Metagenomi. Metagenomi is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FibroBiologics	N/A	N/A	-$18.65M	-$5.19	N/A
Metagenomi	$25.21M	1.77	-$87.87M	-$2.49	N/A

FibroBiologics has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -63.65% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FibroBiologics	N/A	-536.78%	-225.12%
Metagenomi	-384.61%	-63.65%	-44.52%

In the previous week, FibroBiologics had 2 more articles in the media than Metagenomi. MarketBeat recorded 5 mentions for FibroBiologics and 3 mentions for Metagenomi. Metagenomi's average media sentiment score of 1.60 beat FibroBiologics' score of 0.37 indicating that Metagenomi is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
FibroBiologics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Metagenomi	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

FibroBiologics has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market. Comparatively, Metagenomi has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market.

FibroBiologics currently has a consensus target price of $73.00, indicating a potential upside of 4,546.72%. Metagenomi has a consensus target price of $6.00, indicating a potential upside of 408.47%. Given FibroBiologics' higher probable upside, research analysts plainly believe FibroBiologics is more favorable than Metagenomi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FibroBiologics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Metagenomi beats FibroBiologics on 8 of the 14 factors compared between the two stocks.

How does FibroBiologics compare to Invizyne Technologies?

Invizyne Technologies (NASDAQ:IZTC) and FibroBiologics (NASDAQ:FBLG) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

In the previous week, FibroBiologics had 4 more articles in the media than Invizyne Technologies. MarketBeat recorded 5 mentions for FibroBiologics and 1 mentions for Invizyne Technologies. FibroBiologics' average media sentiment score of 0.37 beat Invizyne Technologies' score of 0.00 indicating that FibroBiologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Invizyne Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
FibroBiologics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Invizyne Technologies' return on equity of 0.00% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invizyne Technologies	N/A	N/A	N/A
FibroBiologics	N/A	-536.78%	-225.12%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
FibroBiologics	N/A	N/A	-$18.65M	-$5.19	N/A

FibroBiologics has a consensus target price of $73.00, indicating a potential upside of 4,546.72%. Given FibroBiologics' stronger consensus rating and higher possible upside, analysts plainly believe FibroBiologics is more favorable than Invizyne Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
FibroBiologics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

Summary

FibroBiologics beats Invizyne Technologies on 5 of the 7 factors compared between the two stocks.

How does FibroBiologics compare to Gossamer Bio?

Gossamer Bio (NASDAQ:GOSS) and FibroBiologics (NASDAQ:FBLG) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

In the previous week, Gossamer Bio had 3 more articles in the media than FibroBiologics. MarketBeat recorded 8 mentions for Gossamer Bio and 5 mentions for FibroBiologics. FibroBiologics' average media sentiment score of 0.37 beat Gossamer Bio's score of -0.13 indicating that FibroBiologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gossamer Bio	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
FibroBiologics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Gossamer Bio presently has a consensus price target of $256.00, suggesting a potential upside of 2,337.17%. FibroBiologics has a consensus price target of $73.00, suggesting a potential upside of 4,546.72%. Given FibroBiologics' higher probable upside, analysts clearly believe FibroBiologics is more favorable than Gossamer Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
FibroBiologics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

81.2% of Gossamer Bio shares are held by institutional investors. 3.7% of Gossamer Bio shares are held by company insiders. Comparatively, 7.3% of FibroBiologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Gossamer Bio has a beta of 2, suggesting that its stock price is 100% more volatile than the broader market. Comparatively, FibroBiologics has a beta of 1.65, suggesting that its stock price is 65% more volatile than the broader market.

FibroBiologics has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%. Gossamer Bio's return on equity of 0.00% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-235.00%	N/A	-112.04%
FibroBiologics	N/A	-536.78%	-225.12%

FibroBiologics has lower revenue, but higher earnings than Gossamer Bio. Gossamer Bio is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$48.47M	0.63	-$170.37M	-$0.70	N/A
FibroBiologics	N/A	N/A	-$18.65M	-$5.19	N/A

Summary

Gossamer Bio beats FibroBiologics on 10 of the 15 factors compared between the two stocks.

How does FibroBiologics compare to Mereo BioPharma Group?

Mereo BioPharma Group (NASDAQ:MREO) and FibroBiologics (NASDAQ:FBLG) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

FibroBiologics has lower revenue, but higher earnings than Mereo BioPharma Group. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mereo BioPharma Group	$500K	89.75	-$41.88M	-$0.04	N/A
FibroBiologics	N/A	N/A	-$18.65M	-$5.19	N/A

Mereo BioPharma Group's return on equity of -74.82% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mereo BioPharma Group	N/A	-74.82%	-64.28%
FibroBiologics	N/A	-536.78%	-225.12%

In the previous week, FibroBiologics had 4 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 5 mentions for FibroBiologics and 1 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 0.94 beat FibroBiologics' score of 0.37 indicating that Mereo BioPharma Group is being referred to more favorably in the media.

Company	Overall Sentiment
Mereo BioPharma Group	Positive
FibroBiologics	Neutral

62.8% of Mereo BioPharma Group shares are owned by institutional investors. 6.5% of Mereo BioPharma Group shares are owned by company insiders. Comparatively, 7.3% of FibroBiologics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Mereo BioPharma Group has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market. Comparatively, FibroBiologics has a beta of 1.65, indicating that its stock price is 65% more volatile than the broader market.

Mereo BioPharma Group presently has a consensus target price of $1.67, suggesting a potential upside of 493.12%. FibroBiologics has a consensus target price of $73.00, suggesting a potential upside of 4,546.72%. Given FibroBiologics' higher possible upside, analysts clearly believe FibroBiologics is more favorable than Mereo BioPharma Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mereo BioPharma Group	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
FibroBiologics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

Summary

Mereo BioPharma Group beats FibroBiologics on 8 of the 14 factors compared between the two stocks.

Get FibroBiologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FBLG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FBLG vs. The Competition

Export

Metric	FibroBiologics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$10.58M	$3.87B	$7.20B	$12.67B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-0.31	15.12	275.02	25.43
Price / Sales	N/A	1,415.04	638.08	88.25
Price / Cash	N/A	43.64	28.42	34.96
Price / Book	0.85	15.06	10.32	6.23
Net Income	-$18.65M	-$22.86M	$3.50B	$358.31M
7 Day Performance	-13.20%	-2.17%	-2.41%	-1.59%
1 Month Performance	48.21%	1.84%	0.22%	-2.89%
1 Year Performance	-85.53%	42.42%	24.17%	8.22%

FibroBiologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FBLG FibroBiologics	2.3347 of 5 stars	$1.57 -2.4%	$73.00 +4,546.7%	-85.2%	$10.58M	N/A	N/A	10	Short Interest Increase
CELU Celularity	0.3002 of 5 stars	$1.55 -7.7%	$6.00 +287.1%	-39.2%	$44.87M	$26.55M	N/A	220	Short Interest Increase Gap Down
MGX Metagenomi	4.1949 of 5 stars	$1.17 -0.4%	$6.00 +415.0%	-37.6%	$44.01M	$25.21M	N/A	236
IZTC Invizyne Technologies	N/A	$6.85 +0.7%	N/A	-49.2%	$42.83M	N/A	N/A	29
GOSS Gossamer Bio	2.3439 of 5 stars	$0.18 +2.1%	$3.20 +1,687.7%	-96.1%	$42.01M	$48.47M	N/A	180	Analyst Upgrade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FBLG) was last updated on 9/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

FibroBiologics (FBLG) Competitors

FBLG vs. CELU, MGX, IZTC, GOSS, and MREO

How does FibroBiologics compare to Celularity?

Summary

How does FibroBiologics compare to Metagenomi?

Summary

How does FibroBiologics compare to Invizyne Technologies?

Summary

How does FibroBiologics compare to Gossamer Bio?

Summary

How does FibroBiologics compare to Mereo BioPharma Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBLG vs. The Competition

FibroBiologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

FibroBiologics (FBLG) Competitors

FBLG vs. CELU, MGX, IZTC, GOSS, and MREO

How does FibroBiologics compare to Celularity?

Does the media prefer CELU or FBLG?

Which has better earnings and valuation, CELU or FBLG?

Do insiders & institutionals believe in CELU or FBLG?

Which has more volatility and risk, CELU or FBLG?

Do analysts recommend CELU or FBLG?

Is CELU or FBLG more profitable?

Summary

How does FibroBiologics compare to Metagenomi?

Which has higher valuation & earnings, FBLG or MGX?

Is FBLG or MGX more profitable?

Does the media refer more to FBLG or MGX?

Which has more risk and volatility, FBLG or MGX?

Do analysts rate FBLG or MGX?

Summary

How does FibroBiologics compare to Invizyne Technologies?

Does the media favor IZTC or FBLG?

Is IZTC or FBLG more profitable?

Which has better valuation & earnings, IZTC or FBLG?

Do analysts prefer IZTC or FBLG?

Summary

How does FibroBiologics compare to Gossamer Bio?

Does the media refer more to GOSS or FBLG?

Do analysts rate GOSS or FBLG?

Do insiders and institutionals have more ownership in GOSS or FBLG?

Which has more volatility and risk, GOSS or FBLG?

Is GOSS or FBLG more profitable?

Which has higher earnings and valuation, GOSS or FBLG?

Summary

How does FibroBiologics compare to Mereo BioPharma Group?

Which has stronger valuation & earnings, MREO or FBLG?

Is MREO or FBLG more profitable?

Does the media prefer MREO or FBLG?

Do insiders & institutionals hold more shares of MREO or FBLG?

Which has more volatility & risk, MREO or FBLG?

Do analysts rate MREO or FBLG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBLG vs. The Competition

FibroBiologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools